Pharmacotherapy

Schwartz, Robert P.; Mitchell, Shannon Gwin; Gordon, Michael S.; Kinlock, Timothy W.

doi:10.1007/978-1-4419-9470-7_15

Cited by 2 publications

(2 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(32) While methadone and buprenorphine treatments have proven efficacy, they are not desired by many opioid-dependent individuals. (33) Furthermore, in the United States, many jail and prison officials, including medical providers(17,34) and many probation and parole officers(9,35) are not willing to refer probationers and parolees for agonist-based treatments. The clinical usefulness of oral naltrexone has been challenged due to poor adherence(36,37) and lack of acceptance, especially within the criminal justice setting.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A Multisite Pilot Study of Extended-Release Injectable Naltrexone Treatment for Previously Opioid-Dependent Parolees and Probationers

et al. 2012

Self Cite

View full text Add to dashboard Cite

A feasibility study was conducted to pilot test the ability of five sites to recruit, treat, and retain opioid-dependent offenders in a trial of extended-release injectable naltrexone (XR-NTX). The participants, 61 previously opioid-dependent individuals under legal supervision in the community, received up to six monthly injections of Depotrex® brand naltrexone and completed a six-month follow-up interview. Six-month outcomes showed that those who completed treatment had significantly fewer opioid-positive urines and were less likely to have been incarcerated than those who had not completed treatment. The findings indicate that XR-NTX holds promise as a feasible, effective treatment option for opioid-dependent offenders.

show abstract

Section: Discussionmentioning

confidence: 99%

“…(3,7–9) However, these opioid receptor agonist medications have limitations. For example, there is evidence that some patients continue to use illicit drugs (mainly cocaine) while receiving these treatments.…”

Section: Introductionmentioning

confidence: 99%